2002
DOI: 10.1128/aac.46.2.283-287.2002
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of TAK-457, a Novel Intravenous Triazole, against Invasive Pulmonary Aspergillosis in Neutropenic Mice

Abstract: On the other hand, amphotericin B at 1 mg/kg which was a maximum tolerable dose showed slight but not significant prolongation of survival time of mice, although it also reduced the lung chitin levels and the plasma ␤-D-glucan levels to a lower extent but still significantly. These results suggest that TAK-457 is a promising candidate for development for the treatment of invasive aspergillosis in humans.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2004
2004
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 32 publications
0
6
0
Order By: Relevance
“…[10] Besides the marketed drug of Cresemba, many 1,2,4-triazolium salts have been developed as prodrugs from triazole fungicides. [4,17,[22][23][24] These 1,2,4-triazolium salts have good water solubility and can be rapidly and safely converted into antifungal triazole drugs in living organisms. In 2001, Ichikawa [4] et al synthesized a new antifungal prodrug 1 (TAK-457) for injection with sufficient solubility (4-10 mg/mL in 5 % glucose), stability (1.8 % of TKA-456 after 1 d in 5 % glucose), and high in vivo inhibitory index against Candida albicans TA and Aspergillus fumigatus 437, with the ED 50 (the dose of the test compound which allows 50 % survival of the infected mice) values of 0.62 and 4.49 mg/kg (Figure 2).…”
Section: Antifungal Activities Of Mono-124-triazolium Saltsmentioning
confidence: 99%
“…[10] Besides the marketed drug of Cresemba, many 1,2,4-triazolium salts have been developed as prodrugs from triazole fungicides. [4,17,[22][23][24] These 1,2,4-triazolium salts have good water solubility and can be rapidly and safely converted into antifungal triazole drugs in living organisms. In 2001, Ichikawa [4] et al synthesized a new antifungal prodrug 1 (TAK-457) for injection with sufficient solubility (4-10 mg/mL in 5 % glucose), stability (1.8 % of TKA-456 after 1 d in 5 % glucose), and high in vivo inhibitory index against Candida albicans TA and Aspergillus fumigatus 437, with the ED 50 (the dose of the test compound which allows 50 % survival of the infected mice) values of 0.62 and 4.49 mg/kg (Figure 2).…”
Section: Antifungal Activities Of Mono-124-triazolium Saltsmentioning
confidence: 99%
“…Mice were immunosuppressed with a single dose of the glucocorticoid triamcinolone acetonide (40 mg/kg of body weight injected subcutaneously in the nape of the neck on day Ϫ1) (14, 59) and a single dose of cyclophosphamide (150 mg/kg injected intraperitoneally on day Ϫ3) (12,18,19,24,30,47). The mice were anesthetized with 3.5% isofluorane and inoculated intranasally with 10 5 conidia on day 0, and mortality was monitored for the next 14 days.…”
Section: Methodsmentioning
confidence: 99%
“…The murine model described here is unique in that infection is initiated with a relatively small infectious inoculum, and consequently, the duration of infection is significantly longer than in models of IA which use a higher inoculum (10 4 to 10 9 depending on immunosuppressive regimen and strain of A. fumigatus) to initiate infection and result in a more precipitous course of disease (3,5,7). The initiation of infection with an inoculum that approximates that of human infection has important implications for the testing of novel therapeutics and diagnostic strategies.…”
Section: Efficacy Of Ambmentioning
confidence: 99%